Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Net Income: 2017-2024

Historic Net Income for Apellis Pharmaceuticals (APLS) over the last 8 years, with Dec 2024 value amounting to -$197.9 million.

  • Apellis Pharmaceuticals' Net Income rose 475.46% to $215.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.0 million, marking a year-over-year increase of 117.98%. This contributed to the annual value of -$197.9 million for FY2024, which is 62.57% up from last year.
  • According to the latest figures from FY2024, Apellis Pharmaceuticals' Net Income is -$197.9 million, which was up 62.57% from -$528.6 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Net Income peaked at -$197.9 million during FY2024, and registered a low of -$746.4 million during FY2021.
  • Its 3-year average for Net Income is -$459.6 million, with a median of -$528.6 million in 2023.
  • Per our database at Business Quant, Apellis Pharmaceuticals' Net Income crashed by 116.41% in 2021 and then skyrocketed by 62.57% in 2024.
  • Apellis Pharmaceuticals' Net Income (Yearly) stood at -$344.9 million in 2020, then slumped by 116.41% to -$746.4 million in 2021, then rose by 12.62% to -$652.2 million in 2022, then rose by 18.94% to -$528.6 million in 2023, then skyrocketed by 62.57% to -$197.9 million in 2024.